After a month of intense conversations and negotiations, the Senate Homeland Security and Governmental Affairs Committee (HSGAC) will bring the 'Fair Access to Science and Technology Research (FASTR) Act' up for mark-up on July 29, 2015. The language that will be considered is an amended version of FASTR, officially known as the 'Johnson-Carper Substitute Amendment,' which was officially filed by the HSGAC leadership late on July 24, 2015, per committee rules.
There are two major changes from the original bill language to be particularly aware of. Specifically, the amendment replaces the six month embargo period with 'no later than 12 months, but preferably sooner,' as anticipated; and provides a mechanism for stakeholders to petition federal agencies to 'adjust' the embargo period if the12 months does not serve 'the public, industries, and the scientific community.'
The language requiring a GOA analysis of the desirability of all agencies adopting CC-BY license remains intact, as does the language directing the agencies to control the ultimate location of their funded articles.
STM publisher Elsevier and the American Dairy Science Association have announced the winners of the fifth annual Journal of Dairy Science® (JDS) Most-Cited Awards. Papers published in JDS throughout 2012 were eligible and citations from date of publication until April 15, 2015 were taken into consideration. Awards are conferred in each of the four sections comprising the journal's content: Dairy Foods; Physiology and Management; Nutrition, Feeding and Calves; and Genetics and Breeding.
The 2015 Most-Cited Awards were presented by Journal of Dairy Science Editor-in-Chief, Matthew Lucy on July 14 at the 2015 ADSA ASAS Joint Annual Meeting (JAM), Orlando, FL, July 12-16.
Global healthcare knowledge provider BMJ has announced a partnership with the European Society for Medical Oncology (ESMO), with the aim of publishing a new open access cancer journal - ESMO Open - from next year.
ESMO has over 10,000 members from over 130 countries, working in cancer care and research, and the new title will be its second official journal after the Annals of Oncology. ESMO Open represents a first in this field for BMJ, which now has a stable of more than 50 peer reviewed specialist and open access journals in addition to its flagship title The BMJ.
The new title will publish original research covering the full spectrum of cancer treatment, including medical, radiation, and surgical oncology. In common with BMJ's other open access titles, ESMO Open will include a wide range of material that isn't always available in more traditional outlets, including study protocols and phase I clinical trials, meta-analyses, small or specialist studies, and interesting case studies.
ESMO Open will also offer a platform for ESMO and other partner societies at national and international level to publish important policy papers for sharing with the cancer care community at large. The title will operate a fast submission and review process, with continuous publication online, ensuring that up to date high quality research is rapidly available worldwide.
London-based data repository organisation Figshare and DuraSpace will host a webinar to discuss the possibilities for integration between Figshare for Institutions and DuraCloud. The webinar, scheduled for August 20, from 7pm – 8pm BST, will be presented by Dan Valen, Product Specialist, Figshare, and Carissa Smith, Product Manager, DuraCloud. It will cover the integration and show how the collaboration combines the end-user experience of Figshare with the powerful storage, management, and preservation functionalities of DuraCloud.
With Figshare for Institutions, universities and colleges can manage their research outputs from point of creation and data management plan through to its publication and subsequent impact. DuraCloud automatically copies institutional content onto several different cloud storage providers. The Figshare and DuraCloud collaboration will then ensure all of the captured data is managed and preserved appropriately to align with institutional and funder policies.
Figshare, along with Digital Science, is a member of the DuraSpace not-for-profit organisation whose mission is to support open source technologies and services that promote durable, persistent access to the scholarly record.
In a special free issue of Future Medicinal Chemistry, leading experts explore current and potential new treatment options for the deadly neglected tropical disease schistosomiasis. The journal is published by Future Science Group.
In this issue, experts discuss drug discovery and development advances towards addressing schistosomiasis, also known as bilharzia, a disease caused by parasitic worms. Schistosomiasis is the world's most deadly neglected tropical disease, killing an estimated 280,000 people annually in the African region alone, and is the second most common parasitic disease after malaria. Clinicians now rely solely on the drug praziquantel for treatment and control of schistosomiasis.
Future Medicinal Chemistry provides a monthly point of access to commentary and debate for the ever-expanding and diversifying medicinal chemistry field, enriched by the collaborative efforts of experts from a wide spectrum of specialist areas, including chemoinformaticians, physical chemists, molecular biologists and pharmacologists. The journal showcases milestones in pharmaceutical R&D and features expert analysis of emerging research – from the identification of targets, through to the discovery, design, synthesis and evaluation of bioactive agents.